Replies to post #411301 on Amarin Corp Plc (AMRN)

[rosemountbomber]

So true PD. The generic in the US is only approved for VHTG, but is gobbling up scripts for CVD, so you are correct that the same will occur in China - except quicker.

[AGORDON]

The information in my post came from the Eddingpharm document. I did not render any opinions.

[JRoon71]

Agreed. I would estimate that Amarin records zero revenue from any China sales of Vascepa, save for maybe what is left of milestone payments, which is contractual.

And even if we do record some revenue, it is only a small royalty.

Any substantial revenue in China would be years away, at best. The company will be sold before we see any revenue from sales of V.

[CaptBeer]

Mark,
I agree with you that China can't be trusted with honoring Amarin's IP. However, that's the risk we all have to take. Pfizer, for example has a huge presence in China with many patented drugs not being stolen by China (yet).

As to Amarin's partnership with Eddingpharm:

I’m not the expert on this, but if either party wants to terminate the agreement in December, that event will not affect Amarin’s IP rights. As I said above, China may steal Amarin’s IP in either case, but if Eddingpharm’s distribution rights are terminated then Amarin will be free to find another partner, Pfizer, for example, or simply be clear of Eddingpharm for a BO. China is huge and worth the risk, IMO

[Meowza]

BigPDude--good point about China's respect for IP relative to U.S., you are truly brilliant for conceiving that insight ;-)